Melis Yağdıran

Dr. Melis Yağdıran

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in Medicina
Verified
Journal Article
Open access
PDF file
GSGurgun Tuğçe Vural Solak
Gurgun Tuğçe Vural Solak
KAKurtuluş Aksu
Kurtuluş Aksu
MYMelis Yağdıran
Melis Yağdıran
FÇFatma Dindar Çelik
Fatma Dindar Çelik
ÖAÖzgür Akkale
Özgür Akkale
YSYavuzalp Solak
Yavuzalp Solak
Background and Objectives: Drug provocation tests (DPTs) diagnose drug hypersensitivity reactions (DHRs) and identify safe alternatives. DHRs contribute to patient anxiety. The aim of this study was to evaluate anxiety and hopelessness levels before and after DPT and to examine patients’ avoidance characteristics of the tested drugs. Materials and Methods: Patients undergoing DPT were included. The State–Trait Anxiety Inventory (STAI) assessed anxiety, and the Beck Hopelessness Scale measured hopelessness. Demographic and clinical data, pre- and post-DPT scores, the status of using the medication provided after DPT, and the reason for not using it were analyzed. Results: Seventy-nine patients (60 female, 75.9%) participated. Patients’ Beck Hopelessness Scale, STAI–State, and STAI–Trait scores decreased significantly after the DPT compared to the initial scores. Among the patients who developed a reaction during the drug provocation test, the rate of those whose scale scores increased was significantly higher than the rate of those who did not develop a reaction. A total of 42 patients (53.2%) did not use the alternative safe drug. Of these, six (14.3%) reported that their reluctance stemmed from a fear of experiencing a reaction similar to their initial adverse event. Patients with concomitant allergic diseases were less likely to use alternative safe drugs. Conclusions: DPT reduces long-term anxiety and hopelessness. However, one in seven patients avoids the prescribed safe drug due to fear of recurrence. Effective communication, especially with patients who have allergic conditions or experience a reaction during DPT, and psychological support may improve adherence to the tested medication.

8 May 2025 in Journal of Asthma
Verified
Journal Article
Closed access
FÇFatma Dindar Çelik
Fatma Dindar Çelik
KAKurtuluş Aksu
Kurtuluş Aksu
EÇEnes Çelik
Enes Çelik
HTHATICE CELIK TUGLU
HATICE CELIK TUGLU
MYMelis Yağdıran
Melis Yağdıran
FAFunda Aksu
Funda Aksu
Real-life studies are needed to evaluate the clinical outcomes of add-on tiotropium therapy in patients with asthma. The effects of adding tiotropium bromide to the treatment of asthmatic patients on pulmonary functions and asthma control using real-life data. In a retrospective study, spirometric measures and asthma control states were compared before and one year after of tiotropium treatment in asthmatic adults whose disease was not adequately controlled with a combination of inhaled corticosteroids and long-acting β2-agonists. One year after tiotropium treatment, mean FEV1, FEV1%, and FEV1/FVC ratio increased significantly compared to pretreatment values. Among 32 patients added tiotropium due to symptomatic asthma, 28 (87.5%) patients achieved well-controlled (ACT ≥ 20) end of the year and GINA treatment step-down in 4 (12.5%) patients. Monoclonal antibody therapies (mepolizumab or omalizumab) were initiated in 9 patients (28.1%). FEV1 values and FEV1/FVC ratios showed a statistically significant improvement from baseline measurements obtained prior to the initiation of tiotropium therapy, independent of monoclonal antibody use (p < 0.001 for each). The mean age of these patients was 48.78 ± 11.64 (range: 28 - 81) years, and 25 (78.1%) of them were female. Tiotropium bromide is an effective and reliable add-on therapy for symptomatic asthma when combined with ICS plus LABA, also leads to improvements in respiratory function and asthma control.

8 March 2024 in Anatolian Current Medical Journal
Verified
Journal Article
Open access
PDF file
GBGözde Köycü Buhari
Gözde Köycü Buhari
SBSakine Nazik Bahçecioğlu
Sakine Nazik Bahçecioğlu
SGSelcan Gültuna
Selcan Gültuna
ÖAÖzgür Akkale
Özgür Akkale
HTHATICE CELIK TUGLU
HATICE CELIK TUGLU
KAKurtuluş Aksu
Kurtuluş Aksu
Aims: This study aims to define characteristics of hypersensitivity reactions with etoposide, and outcomes of desensitizations in immediate-type hypersensitivity rections Methods: This is a retrospective observational study of patients who had hypersensitivity reactions with etoposide from January 2019 to December 2023. Results: A total of 39 patients with lung cancer were included in the study. Ten (25.6%) patients had known other drug allergies and three (7.7%) patients had previous chemotherapeutic hypersensitivity two with paclitaxel and one with docetaxel. Most of the initial hypersensitivities were in the first or second cycle (n=29, 74.4%). Ten (25.4%) patients had hypersensitivity reactions at the first application of etoposide. Thirty (76.9%) patients had immediate-type hypersensitivity reactions. There was no significant difference in terms of patient and initial hypersensitivity characteristics between patients who had immediate or non-immediate type hypersensitivity reactions. Of the 30 patients with immediate-type hypersensitivity reactions, initial reaction was mild in 16 (53.3%) and moderate in 14 (46.7%) patients. Most common symptoms were erythema in 29 (96.7%), dyspnea in 13 (43.3%), chest tightness in 8 (26.7%), discomfortness in 7 (23.3%), and hypertension in 6 (20%). Skin tests were negative in five patients who underwent skin testing. A total of 98 desensitization courses were performed in 27 patients and 3 (11.1%) patients had breakthrough reactions. Conclusion: Most of the hypersensitivity reactions to etoposide are immediate-type and not severe. Desensitization is an effective and safe procedure to manage these reactions. Further research is needed to elucidate the mechanisms of hypersensitivity reactions.

28 May 2021
Verified
Preprint
Open access
PDF file
MYMelis Yağdıran
Melis Yağdıran
EPEbru Sengul Parlak
Ebru Sengul Parlak
HHH.CAnan Hasanoglu
H.CAnan Hasanoglu
ÖEÖzcan Erel
Özcan Erel
Background: Community-acquired pneumonia (CAP) is an important public health problem because of its high morbidity, mortality, and health care costs. Many biomarkers have been used to determine the severity and prognosis of pneumonia. Ischemia-modified albumin (IMA) is a marker of the recently used oxidant-antioxidant mechanism and has been found to increase in many inflammatory conditions. Objectives: To investigate the role of the levels of IMA in CAP and to evaluate its relationship with pneumonia severity. Methods: A total of 150 patients with a diagnosis of CAP and 150 healthy individuals were included in the study. IMA levels were evaluated in both groups. The patients with CAP were divided into ambulatory, ward and intensive care groups, and their IMA levels were compared. Results: There was no significant difference between the two groups in terms of age or gender (p > 0.05 for both). No significant difference was observed in the IMA levels of the patient and control groups (p ˃ 0.05). The lowest IMA level was observed in the ambulatory group (p = 0.001). When the patients in the ambulatory and hospitalized (ward and intensive care together) groups were evaluated, the cut-off value of IMA was 77.60 ABSU, sensitivity was 64.9%, specificity was 75.0%, positive predictive value was 89.2%, and negative predictive value was 40.3%. Conclusion: In the management of patients with CAP, IMA seems to be a useful marker for CAP severity and hospitalization decision. Keywords: Community-acquired pneumonia, ischemia-modified albumin, biomarker

14 August 2026 in Medicina
Verified
Journal Article
Open access
PDF file
MYMelis Yağdıran
Melis Yağdıran
KAKurtuluş Aksu
Kurtuluş Aksu
Background and Objectives: A considerable proportion of patients with asthma remain inadequately controlled despite treatment with inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) therapy. Single-inhaler triple therapy comprising an inhaled corticosteroid, a long-acting β2-agonist, and a long-acting muscarinic antagonist (ICS/LABA/LAMA) has emerged as an effective step-up treatment; however, real-world evidence remains limited. This study aimed to evaluate the effects of transitioning from high-dose ICS/LABA therapy to single-inhaler triple therapy on asthma control, lung function, and exacerbation-related outcomes in routine clinical practice. Materials and Methods: This retrospective observational study included adult patients with uncontrolled asthma who were switched from high-dose ICS/LABA therapy to single-inhaler triple therapy at a tertiary referral center. Demographic characteristics, Asthma Control Test (ACT) scores, pulmonary function tests, blood eosinophil counts, exacerbation frequency, oral corticosteroid (OCS)-requiring exacerbations, short-acting β2-agonist (SABA) use, emergency department visits, and hospitalizations were compared before and after treatment escalation using paired statistical analyses. Results: Nineteen patients (mean age 58.9 ± 10.4 years; 63.2% female) were included. Following transition to single-inhaler triple therapy, asthma control improved significantly, with mean ACT scores increasing from 14.8 ± 3.2 to 23.4 ± 3.6 (p < 0.001). Mean forced expiratory volume in one second (FEV1) increased from 1692.6 ± 722.7 mL to 2020.5 ± 871.5 mL, while predicted FEV1 improved from 64.2 ± 21.2% to 75.6 ± 21.6% (both p < 0.001). Total annual exacerbation frequency decreased from a median of 2 (interquartile range [IQR], 1–3) to 0 (IQR, 0–1; p = 0.0005), and 78.9% of patients experienced at least one fewer exacerbation. Significant reductions were also observed in OCS-requiring exacerbations, SABA use, emergency department visits, hospitalizations, and blood eosinophil counts. Conclusions: In this real-world cohort, transitioning from ICS/LABA therapy to single-inhaler triple therapy was associated with statistically significant improvements in asthma control and lung function, together with substantial reductions in exacerbation burden and healthcare utilization. These findings support the effectiveness of single-inhaler triple therapy as a step-up treatment strategy for patients with uncontrolled asthma in routine clinical practice.

30 July 2025 in Bratislava Medical Journal
Verified
Journal Article
Closed access
PDF file
MYMelis Yağdıran
Melis Yağdıran
KAKurtuluş Aksu
Kurtuluş Aksu
HTHATICE CELIK TUGLU
HATICE CELIK TUGLU
ÖAÖzgür Akkale
Özgür Akkale
FÇFatma Dindar Çelik
Fatma Dindar Çelik
FAFunda Aksu
Funda Aksu